← Special Reports
CardiologyHeart Failure

HFpEF Finally Has Answers: Finerenone, SGLT2s, and What Comes Next

The largest unmet need in cardiology finally has a multi-drug evidence base

SR-2026-005
EditorMara Voss
CopywritersEditorial Team
Coming Soon

HFpEF Finally Has Answers: Finerenone, SGLT2s, and What Comes Next

The largest unmet need in cardiology finally has a multi-drug evidence base

Why We Are Covering This

HFpEF has moved from a disease with no proven therapy to one with two FDA-approved drug classes and a third in Phase 3 trials within 24 months. Cardiologists and internists are now updating treatment algorithms in real time.

What to Expect

You will leave with a working treatment algorithm for HFpEF, clarity on where finerenone and SGLT2 inhibitors fit relative to each other, and a view of what GLP-1 Phase 3 data could add to practice.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first
The Life Science Feed
thelifesciencefeed.com · Special Report
SR-2026-00507/26

Related Articles

Universal Heart Failure Definition Issued by Global SocietiesHeart Failure

Universal Heart Failure Definition Issued by Global Societies

Four major cardiology societies released a universal definition of heart failure, aiming to standardise diagnosis and research across the globe.

10 min readGet the full story
Novel Therapies Target Atherogenic Lp(a) ParticleCoronary Artery Disease

Novel Therapies Target Atherogenic Lp(a) Particle

Emerging therapeutic strategies are shifting focus from LDL cholesterol to apoB, targeting Lp(a) and other atherogenic particles.

11 min readGet the full story
Vitamin K2 Supplementation May Curb Coronary CalcificationCoronary Artery Disease

Vitamin K2 Supplementation May Curb Coronary Calcification

Evidence suggests vitamin K2 supplementation may reduce coronary artery calcification, a key marker of cardiovascular disease risk.

12 min readGet the full story
AI-Assisted Fetal Echocardiography Improves Early CHD DetectionAortic Valve Stenosis

AI-Assisted Fetal Echocardiography Improves Early CHD Detection

Artificial intelligence (AI) integration into fetal echocardiography improves early detection of congenital heart disease (CHD), including aortic stenosis.

8 min readGet the full story
    0:00 / 0:00